Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and Preliminary Efficacy of INR102 Injection in Patients With Prostate-specific Membrane Antigen (PSMA)-Positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06970119 is registered in ClinicalTrials.gov with Yunhe Pharmaceutical (Tianjin) Co., Ltd as lead sponsor.

NCT NCT06970119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06970119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and Preliminary Efficacy of INR102 Injection in Patients With Prostate-specific Membrane Antigen (PSMA)-Positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 14, 2025
Completion date
October 22, 2029
Enrollment
55 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer